Purchase Order 75N95C22P00053

The Department of Health and Human Services Food and Drug Administration awarded a $25,025 firm fixed price purchase order to Nanocomposix, LLC for the production of amino-functionalized silica nanoparticles for in vivo analysis of blood-brain barrier safety and integrity. Performance will take place in Silver Spring, Maryland by September 15, 2023. No set-aside designation was applied to this contract for Nanocomposix to deliver amino-functionalized silica nanoparticles to the FDA, presumably...

Nanocomposix, Inc. was awarded a $300,000 firm fixed price Small Business Innovation Research Phase I contract from the National Institutes of Health's National Institute of Allergy and Infectious Diseases. This contract is in response to a solicitation seeking proposals for research and development of alternatives to cell culture materials, cancer immunotherapy manufacturing methods, and other biomedical technologies. Specifically, Nanocomposix will design and synthesize a new PLGA-based...

This SBIR Phase II contract was awarded by the National Cancer Institute (NCI), a component of the U.S. Department of Health and Human Services, to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles. The $997,267 cost-plus-fixed-fee contract is for the development of "bright, photostable surface enhanced fluorescent nanotags" to advance biomedical technologies. Nanocomposix has previously provided products and R&D services to NCI, FDA, CDC, and the...

This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a component of the U.S. Department of Health and Human Services, to Nanoscale Corporation. The $831,900 contract is for the development of "functionalized bimagnetic core/shell Fe/Fe3O4 stealth nanoparticles" for the diagnosis and treatment of cancer. The contract includes two major subcontractors - Xenometrics, LLC, which will conduct toxicology testing, and the...

This is a Small Business Innovation Research (SBIR) Program Phase I contract awarded by the Department of Health and Human Services (HHS) to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles, for the development of "small hollow nanodelivery vehicles for cancer treatment." The fixed-price contract has a ceiling value of $200,000.00 and a period of performance ending on March 30, 2010. Nanocomposix has previously performed prime contracts and subcontracts for...

This is a $999,999.99 cost-plus-fixed-fee contract awarded by the U.S. Army Medical Command (MEDCOM) to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles. The contract is for a Small Business Innovation Research (SBIR) Phase II program with a target completion date of February 27, 2019. Nanocomposix has previously supported the Department of Defense and Department of Health and Human Services through prime federal contracts and subcontracts, delivering products and...

This is a $1,000,000.00 Phase II SBIR contract awarded by the National Cancer Institute (NCI), a component of the Department of Health and Human Services, to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles. The contract is for the rapid screening of individual cells using single cell mass spectrometry, supporting the NCI's biomedical research and development efforts. Nanocomposix has previously supported other federal agencies such as the Department of Defense...

The Department of Health and Human Services (HHS) Centers for Disease Control and Prevention (CDC) awarded a $249,950.00 firm fixed price purchase order to Nanocomposix, Inc. for the development of a Lateral Assay Device. Nanocomposix is a manufacturer of engineered nanoparticles that has previously supported federal contracts for lateral flow assays, vaccines, and diagnostics. The contract is not set aside for any socioeconomic program. Nanocomposix has produced pilot lots for clinical trials...

This is a $150,000.00 firm fixed-price definitive contract awarded by the U.S. Army Medical Command (MEDCOM) to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles. The contract has a period of performance ending on March 30, 2016. Nanocomposix has provided similar products and services to the Department of Health and Human Services and Department of Defense in the past, including lateral flow assay devices, gold nanoparticles, and research and development for...

This is a Small Business Innovation Research (SBIR) Phase I contract award to Nanocomposix, Inc. by the U.S. Army Medical Command (MEDCOM) for the development of new biomedical technologies. The contract has a firm fixed price of $150,000.00 and a period of performance through March 25, 2017. Nanocomposix, a manufacturer of engineered nanoparticles, has previously received prime federal contracts and grants from agencies such as the Department of Health and Human Services and Department of...